INO-4212

INO-4212 is a polyvalent DNA-based vaccine developed for the prevention and treatment of Ebola virus infections. It consists of two optimized SynCon DNA plasmids (INO-4201 and INO-4202) encoding the glycoprotein antigen from various circulating Ebola strains between 1975 and 2014. The vaccine is designed to stimulate both T cell and antibody immune responses against Ebola virus. In clinical studies, it has demonstrated safety, tolerability, and robust immunogenicity in healthy volunteers. Preclinical studies showed that INO-4212 provided complete protection against lethal Ebola challenge in animal models with long-lasting immune responses detectable for at least one year after vaccination. The vaccine can be administered intramuscularly or intradermally followed by electroporation using a specialized device to enhance cellular uptake of the DNA[1][2][4][5].